Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tenalisib by Rhizen Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Tenalisib by Rhizen Pharmaceuticals for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
Tenalisib by Rhizen Pharmaceuticals for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
Tenalisib by Rhizen Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Tenalisib by Rhizen Pharmaceuticals for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...